Novartis Ag (NVS) Short term Debt (2015 - 2025)
Novartis Ag recorded quarterly Short term Debt of $794.0 million in Q4 2025, up 23.68% quarter-over-quarter from $642.0 million in Q4 2024, and up 23.68% year-over-year from $642.0 million in Q4 2024.
Novartis Ag's Short term Debt history runs 11 years deep, the most recent figure standing at $794.0 million for Q4 2025.
- In Q4 2025, Short term Debt rose 23.68% year-over-year to $794.0 million; the TTM figure through Dec 2025 stood at $794.0 million (up 23.68% YoY), while the FY2025 annual figure was $794.0 million, up 23.68% from the prior year.
- Short term Debt came in at $794.0 million for Q4 2025 at Novartis Ag, up from $642.0 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $6.3 billion in Q4 2021 to a low of $624.0 million in Q4 2023.
- A 5-year average of $2.9 billion and a median of $794.0 million in 2025 frame the typical range for Short term Debt.
- Across the five-year window, Short term Debt soared 177.07% in 2021 and plunged 89.48% in 2023, its largest moves.
- Novartis Ag's Short term Debt stood at $6.3 billion in 2021, then decreased by 5.78% to $5.9 billion in 2022, then slumped by 89.48% to $624.0 million in 2023, then gained by 2.88% to $642.0 million in 2024, then increased by 23.68% to $794.0 million in 2025.
- According to Business Quant data, Short term Debt over the past three periods registered $794.0 million, $642.0 million, and $624.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 794.00 Mn |
| Dec 31, 2024 | 642.00 Mn |
| Dec 31, 2023 | 624.00 Mn |
| Dec 31, 2022 | 5.93 Bn |
| Dec 31, 2021 | 6.30 Bn |
| Dec 31, 2020 | 2.27 Bn |
| Dec 31, 2019 | 719.00 Mn |
| Dec 31, 2018 | 701.00 Mn |
| Dec 31, 2017 | 692.00 Mn |
| Sep 30, 2017 | -80.00 Mn |
| Jun 30, 2017 | -105.00 Mn |
| Mar 31, 2017 | -88.00 Mn |
| Dec 31, 2016 | -129.00 Mn |
| Sep 30, 2016 | -155.00 Mn |
| Jun 30, 2016 | -210.00 Bn |
| Mar 31, 2016 | -289.00 Bn |
| Dec 31, 2015 | -315.00 Mn |
| Sep 30, 2015 | -278.00 Bn |